mesenchymal stem cell therapy-extracellular vesicles (MSC-EV) / Royan Stem Cell Tech - LARVOL DELTA

Sustained and Localized Delivery of Mesenchymal Stem Cells-Derived Extracellular Vesicles by an In Situ Forming Click PEG Hydrogel for Diabetic Nephropathy Therapy. (PubMed, ACS Biomater Sci Eng) - "The MSC-EV-laden PEG hydrogel gradually swelled and released EVs in a sustained manner over one month...Specifically, the hydrogel-mediated delivery of MSC-EVs could significantly enhance antifibrotic effects of MSC-EVs and even prevent and reverse the progression of renal fibrosis in a DN mouse model, an event that was not observed by the free EV treatment. Collectively, this prolonged delivery system may open a new paradigm for improved EV therapies for various chronic diseases."

Journal • Diabetic Nephropathy • Fibrosis • Immunology • Nephrology • Renal Disease

Sustained and localized delivery of mesenchymal stem cells-derived extracellular vesicles by in situ forming PEG click hydrogel for diabetic nephropathy therapy (ERA 2025) - "The MSC-EV-laden PEG hydrogel gradually swelled and released EVs in a sustained manner over one month... Collectively, this prolonged delivery system may open a new paradigm for improved therapies based on MSC-EVs for DN and any other chronic diseases."

Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Immunology • Nephrology • Renal Disease

Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure (clinicaltrials.gov) - P1/2 | N=10 | Recruiting | Sponsor: Royan Institute

New P1/2 trial • Stroma • Women's Health

Higher Chondrogenic Potential of Extracellular Vesicles Derived from Mesenchymal Stem Cells Compared to Chondrocytes-EVs In Vitro. (PubMed, Biomed Res Int) - "The current study aims to evaluate the chondrogenic potential of EVs derived from chondrocytes (Cho-EV) and mesenchymal stem cells (MSC-EV)...Higher expression of chondrogenic specified markers, especially collagen type II (COL II), and secretion of glycosaminoglycans (GAGs) and proteoglycans were observed in MSCs treated with 50 and 100 μg/ml MSC-EVs compared to the Cho-EVs. The results from the use of EVs, particularly MSC-EVs, with high chondrogenic ability will provide a basis for developing therapeutic agents for cartilage repair."

Journal • Preclinical • CD9

Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P2/3; N=60; Recruiting; Sponsor: Royan Institute

Clinical • New P2/3 trial • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases